Although the molecular mechanism of RuvBL1 on regulating c-Jun/AP-1 activation is not fully understood, our studies suggest RuvBL1 to be a potential therapeutic target for TRAIL resistance in NSCLC, which helps to broaden the application of TRAIL. Here, FOS is linked to non-small cell lung carcinoma.